A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously

• ClinicalTrials.gov Identifier: NCT01297192
• Recruitment Status: Completed
• First Posted: February 16, 2011
• Last Update Posted: July 29, 2013
• Sponsor: Astellas Pharma Inc
• Information provided by (Responsible Party): Astellas Pharma Inc

Study Description

Brief Summary:

This study investigates whether mirabegron (YM178) has an effect on the pharmacokinetics of solifenacin and whether solifenacin has an effect on the pharmacokinetics of mirabegron.

Condition or disease	Intervention/treatment	Phase
Healthy Volunteers; Pharmacokinetics of Mirabegron	Drug: solifenacin succinate; Drug: mirabegron	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 41 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: An Open-label, One-sequence, Two-arm Study to Evaluate the Effect of Steady State Concentrations of Mirabegron on the Pharmacokinetics of Solifenacin and to Evaluate the Effect of Steady State Concentrations of Solifenacin on the Pharmacokinetics of Mirabegron in Healthy Young Male and Female Subjects
• Study Start Date: March 2009
• Actual Primary Completion Date: July 2009
• Actual Study Completion Date: July 2009

Arms and Interventions

Arm	Intervention/treatment
Treatment Arm 1; The effect of mirabegron on the pharmacokinetics of solifenacin	Drug: solifenacin succinate; Oral; Other Names: Vesicare; YM905; Drug: mirabegron; Oral; Other Name: YM178
Treatment Arm 2; The effect of solifenacin on the pharmacokinetics of mirabegron	Drug: solifenacin succinate; Oral; Other Names: Vesicare; YM905; Drug: mirabegron; Oral; Other Name: YM178

Outcome Measures

Primary Outcome Measures :

1. Assessment of pharmacokinetics of solifenacin through analysis of blood samples [ Time Frame: Days 1 - 9 and Days 23 - 39 ]
2. Assessment of pharmacokinetics of mirabegron through analysis of blood samples [ Time Frame: Time Frame: Days 1 - 6 and Days 16 - 21 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Male subject must agree to sexual abstinence and/or use a highly effective method of birth control from screening until 3 months after last dose of study medication

• Female subject must be of non-child bearing potential, i.e. post menopausal, surgically sterilized (e.g. tubal ligation), hysterectomy in medical history, or must practice an adequate non-hormonal contraceptive method to prevent pregnancies. Non-hormonal contraceptive methods are defined as:

  • sexual abstinence from 1 month before admission until 3 months after discharge
  • subject's sexual partner has been surgically sterilized (since at least 3 months prior to the screening), or
  • subject is under two (2) of the following contraceptive methods: I. diaphragm with spermicide II. intrauterine device III. sexual partner is using condoms in combination with a spermicidal cream
• Body Mass Index between 18.5 and 30.0 kg/m2, inclusive

Exclusion Criteria:

• Known or suspected hypersensitivity to mirabegron or any of the components of the formulation used
• Known or suspected hypersensitivity to solifenacin succinate or any of the components of the formulation used
• Pregnant or breast feeding within 6 months before screening assessment.
• Any of the liver function tests (i.e. ALT, AST and Alkaline phosphatase) above the upper limit of normal at repeated measures
• Any clinical significant history of or at risk for urinary retention, severe gastro-intestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma
• Any clinically significant history of asthma, eczema, any other clinically significant allergic condition or previous severe hypersensitivity to any drug (excluding non-active hay fever)
• Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic as judged by the medical investigator
• Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests
• Abnormal pulse and/or blood pressure measurements at the pre-study visit as follows: pulse <40 or >90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure >90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically)
• A marked baseline prolongation of QT/QTc interval after repeated measurement of >450 ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT syndrome (LQTS)
• Use of any prescribed or OTC (over-the counter) drugs (including vitamins, oral contraceptives or hormone replacement therapy, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for paracetamol (up to 3 g/day)
• Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit
• Any use of drugs of abuse within 3 months prior to admission to the Clinical Unit
• History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the Clinical Unit
• History of drinking more than 21 units of alcohol per week (1 unit=270 cc of beer or 40 cc of spirits or 1 glass of wine) (>14 units of alcohol for female subjects) within 3 months prior to admission to the Clinical Unit
• Donation of blood or blood products within 3 months prior to admission to the Clinical Unit
• Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2
• Subject who, in the opinion of the investigator, is not likely to complete the trial for any reason
• Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study, provided that the clinical study did not entail a biological compound with a long terminal half life
• Any clinical condition, which, in the opinion of the investigator, would not allow safe completion of the study

Contacts and Locations

Locations

France

Paris, France, 75015

Sponsors and Collaborators

Astellas Pharma Inc

Investigators

• Study Director: Use Central Contact; Astellas Pharma Europe B.V.

More Information

Additional Information:

Link to Results on JAPIC 

• Responsible Party: Astellas Pharma Inc
• ClinicalTrials.gov Identifier: NCT01297192
• Other Study ID Numbers: 178-CL-069; 2008-007929-40 ( EudraCT Number )
• First Posted: February 16, 2011
• Last Update Posted: July 29, 2013
• Last Verified: July 2013

Keywords provided by Astellas Pharma Inc:

YM178; Mirabegron; DDI; Phase I; Solifenacin; Pharmacokinetics; Pharmacokinetics of mirabegron

Additional relevant MeSH terms:

Solifenacin Succinate; Mirabegron; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Urological Agents; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic Agonists; Adrenergic Agents